Scientists craft new peptides to fight diseases with smarter and gentler molecular tools

If needed, please add me on WhatsApp at +852 5487 8366 and I’ll send you our product price list.

 Twin Incretins Unite Against Diabetes and Obesity
 The convergence of GIP and GLP‑1 signalling represents a paradigm shift in treating two intertwined epidemics. These synthetic peptides are designed to harnes the full potential of the incretin system, which had been underutilised in older therapies. When both receptors are activated, the pancreas releases insulin more efficiently, the liver reduces glucose output, and the brain signals satiety more strongly. Clinical evidence demonstrates that this dual approach yields dose‑dependent reductions in both fasting and postprandial glucose, with a lower risk of hypoglycaemia because insulin release is glucose‑dependent.

Concurrently, the weight‑lowering effect is comparable to that of bariatric surgery in some patient subsets. Beyond the classic endpoints, emerging data suggest beneficial effects on renal function and inflammatory markers. The peptide is formulated to resist enzymatic degradation, allowing for a once‑weekly regimen that fits seamlessly into busy lives. With careful dose escalation, most patients tolerate therapy well. As research expands, these twin incretin agonists are poised to become first‑line options, not only for diabetes but also for obesity as a primary disease.